Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
about
Molecular predictive markers in tumors of the gastrointestinal tractState of the Art in the Treatment of Gastrointestinal Stromal Tumors.Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
P2860
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
@en
type
label
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
@en
prefLabel
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
@en
P2860
P356
P1476
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
@en
P2093
John Zalcberg
P2860
P304
P356
10.1177/1758834014544892
P577
2014-09-01T00:00:00Z